NGGT Inc., (“Next Generation Gene Therapeutics” or “NGGT”), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced positive new data on NGGT002, a clinical-stage gene therapy candidate for the treatment of Phenylketonuria (PKU).
Comments are closed.